RE:RE:A New Cancer Treatment.Eoganacht wrote: The same company whose phase 2 pancreatic cancer treatment put Harry Reid into remission are conducting a phase 2 trial for BCG-unresponsive NMIBC. This company, (ImmunityBio), received fast track designation from the FDA in 2017 for the use of their drug N-803 in combination with BCG for BCG-unresponsive NMIBC and they received breakthrough therapy designation in December 2019.
Preliminary Results: 62 patients have been enrolled to date on this trial with 35 patients with CIS (cohort A) and 27 patients with papillary tumor only (cohort B). In cohort A, of 18 evaluable patients, 16 (89%) have achieved CR. In cohort B, of 13 evaluable patients, 10 (77%) demonstrated no disease at their 3-month and 6-month assessment. Of the 8 patients evaluated beyond this time point, no recurrences have been noted. Three treatment-related adverse events (AEs) were reported (infection, anemia, and bacteremia) ranging grades 2-3. None of the patients experienced immune-related AEs. QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) In 2020 they plan to run trials for triple negative breast cancer, lung cancer, head and neck cancer, Merkel cell carcinoma and glioblastoma.
Their treatment is a lot more complicated than TLT's:
"All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. The study duration is 24 months." Estimated completion date: January 2023
skys1 wrote: I'm watching Fox Business News. They just had a lengthy segment on a "breakthrough" cancer treatment that cured Harry Reed(former Dem head of the US Senate) of pancreatic cancer.
We all have this natural killer cell that as part of our immune system attacks, kills, germs, inflammions and such. However cancer T cells have a way to hide from it. They have found a way to re-engineer this killer cell to attack and kill cancer T calls. They expect this new breakthrough which works on all cancers to revolutionize cancer treatments.
The point of all this is the inept management of Theralase better get "on the stick with their Act or they(and us), will be left behind.
Thanks Eoganacht...
I had referred to N-803 a while back as another potential competitor, but only as a combo or neoadjuvant form of immunotherapy (i.e. being given with BCG, modified BCG, checkpoint inhibitor or other therapy).
The downsides are fairly obvious...1). Like with many immunotherapies, it will likely be restricted to combo/neoadjuvant use. 2). It is highly dependent on the "immune health" of the individual, which certainly is not a given in the elderly patient. 2). Manufacturing cost. 3). Requires multiple rounds of expensive treatments in combination (the drug doesn't stick around in the body too long, at least not at therapeutic levels) & because of #3....4). Treatment period never ends (intermittent treatments lasting beyond 18 months post the initial induction treatment).
Guess I just argued myself out of this being a competitor ; ). Good luck...